The ALK Tyrosine Kinase Receptor pipeline drugs market research report outlays comprehensive information on the ALK Tyrosine Kinase Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the ALK Tyrosine Kinase Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Non Malignant Disorders, Genetic Disorders, and Gastrointestinal which include the indications Non-Small Cell Lung Cancer, Solid Tumor, Inflammatory Myofibroblastic Tumor (IMT), Vestibular Schwannoma (Acoustic Neuroma), Neurofibromatoses Type II, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), and Liver Failure (Hepatic Insufficiency). It also reviews key players involved in ALK Tyrosine Kinase Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The ALK Tyrosine Kinase Receptor pipeline targets constitutes close to 40 molecules. Out of which, approximately 31 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 5, 8, 3, 4, 6, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 7, and 2 molecule.
ALK Tyrosine Kinase Receptor overview
ALK tyrosine kinase receptor (ALK) is a protein that transmits signals from the cell surface into the cell. It’s also known as anaplastic lymphoma kinase (ALK) or CD246. ALK transmits signals from the cell surface into the cell through a process called signal transduction.
For a complete picture of ALK Tyrosine Kinase Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
